Antioxidant Supplementation for Erectile Dysfunction: Systematic Review and Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.

IF 4 3区 医学 Q1 ANDROLOGY World Journal of Mens Health Pub Date : 2024-05-16 DOI:10.5534/wjmh.230280
Ranjith Ramasamy, Samir Bhattacharyya, Taylor P Kohn, Larry E Miller
{"title":"Antioxidant Supplementation for Erectile Dysfunction: Systematic Review and Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.","authors":"Ranjith Ramasamy, Samir Bhattacharyya, Taylor P Kohn, Larry E Miller","doi":"10.5534/wjmh.230280","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This meta-analysis aimed to determine the efficacy and safety of antioxidant supplementation for treating erectile dysfunction (ED).</p><p><strong>Materials and methods: </strong>We systematically searched MEDLINE, Embase, and the Cochrane Library for double-blind, randomized, placebo-controlled trials of oral antioxidant supplementation in men with ED. Erectile function was assessed by the International Index of Erectile Function-Erectile Function domain (IIEF-EF) score. Using random-effects meta-analysis models, antioxidant and placebo groups were compared for erectile function using the mean difference in IIEF-EF score adjusted to a 6-30 scale and for side effects using the log risk ratio.</p><p><strong>Results: </strong>The review included 23 trials of 1,583 men (median age 51 years) treated with antioxidant supplementation or placebo for a median of 12 weeks (range, 4 weeks to 6 months). Antioxidant supplementation significantly improved erectile function compared to placebo, with a mean difference of 5.5 points (95% confidence interval [CI]: 3.7 to 7.3; p<0.001) on the IIEF-EF. In meta-regression, the treatment benefit was greater in men with more severe ED (p<0.001). Side effects were uncommon, none were serious, and the frequency was comparable between antioxidant (3.8%) and placebo (2.1%) groups (log risk ratio=0.36; 95% CI: -0.24 to 0.97; p=0.24).</p><p><strong>Conclusions: </strong>Antioxidant supplementation appears safe and significantly improves erectile function in men with ED, particularly those with more severe symptoms. Limitations of this review included unknown long-term efficacy and safety and the inability to make specific product and dosing recommendations due to the variety of antioxidants and regimens studied.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Mens Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5534/wjmh.230280","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANDROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This meta-analysis aimed to determine the efficacy and safety of antioxidant supplementation for treating erectile dysfunction (ED).

Materials and methods: We systematically searched MEDLINE, Embase, and the Cochrane Library for double-blind, randomized, placebo-controlled trials of oral antioxidant supplementation in men with ED. Erectile function was assessed by the International Index of Erectile Function-Erectile Function domain (IIEF-EF) score. Using random-effects meta-analysis models, antioxidant and placebo groups were compared for erectile function using the mean difference in IIEF-EF score adjusted to a 6-30 scale and for side effects using the log risk ratio.

Results: The review included 23 trials of 1,583 men (median age 51 years) treated with antioxidant supplementation or placebo for a median of 12 weeks (range, 4 weeks to 6 months). Antioxidant supplementation significantly improved erectile function compared to placebo, with a mean difference of 5.5 points (95% confidence interval [CI]: 3.7 to 7.3; p<0.001) on the IIEF-EF. In meta-regression, the treatment benefit was greater in men with more severe ED (p<0.001). Side effects were uncommon, none were serious, and the frequency was comparable between antioxidant (3.8%) and placebo (2.1%) groups (log risk ratio=0.36; 95% CI: -0.24 to 0.97; p=0.24).

Conclusions: Antioxidant supplementation appears safe and significantly improves erectile function in men with ED, particularly those with more severe symptoms. Limitations of this review included unknown long-term efficacy and safety and the inability to make specific product and dosing recommendations due to the variety of antioxidants and regimens studied.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
补充抗氧化剂治疗勃起功能障碍:双盲、随机、安慰剂对照试验的系统回顾和元分析》(Systematic Review and Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials)。
目的:本荟萃分析旨在确定补充抗氧化剂治疗勃起功能障碍(ED)的有效性和安全性:我们系统检索了 MEDLINE、Embase 和 Cochrane 图书馆中有关口服抗氧化剂补充剂治疗 ED 男性患者的双盲、随机、安慰剂对照试验。勃起功能通过国际勃起功能指数-勃起功能域(IIEF-EF)评分进行评估。通过随机效应荟萃分析模型,使用调整为6-30分的IIEF-EF评分的平均差异对抗氧化剂组和安慰剂组的勃起功能进行比较,并使用对数风险比对副作用进行比较:研究共纳入了23项试验,1,583名男性(中位年龄为51岁)接受了为期12周(4周至6个月)的抗氧化剂补充剂或安慰剂治疗。与安慰剂相比,补充抗氧化剂能明显改善勃起功能,平均差异为 5.5 分(95% 置信区间 [CI]:3.7至7.3;p结论:补充抗氧化剂似乎是安全的,而且能显著改善男性 ED 患者的勃起功能,尤其是那些症状较为严重的患者。本综述的局限性包括:长期疗效和安全性尚不明确;由于研究的抗氧化剂和治疗方案多种多样,因此无法提出具体的产品和剂量建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Mens Health
World Journal of Mens Health Medicine-Psychiatry and Mental Health
CiteScore
7.60
自引率
2.10%
发文量
92
审稿时长
6 weeks
期刊最新文献
Unlocking the Potential of ChatGPT in Male Sexual Health and Dysfunction: A Hold Endeavor and Comprehensive Study. Postoperative Progress of Deep Grid Incision and Sealing with Collagen Fleece for Treatment of Peyronie's Disease: Prospective Observational Study for 3 Years. Identification of Correlation Between Frailty and Lower Urinary Tract Symptoms in Elderly Male Using Korean-FRAIL Scale. Yes-Associated Protein Promotes Endothelial-Mesenchymal Transition to Mediate Diabetes Mellitus Erectile Dysfunction by Phosphorylating Smad3. Diagnosis and Management of Peyronie's Disease: A Clinical Consensus Statement and Recommendations from the Korean Society for Sexual Medicine and Andrology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1